

Special Issue

Applications of Nanoparticles in Vaccines

Message from the Guest Editors

Nanoparticles have been extensively researched over the last several decades for their potential in vaccine applications. They can be utilized as a delivery system or carrier, and some even have their own self-adjuvating properties. The application of nanoparticles in vaccines is also very topical, given the recent spotlight on lipid nanoparticles for the delivery of mRNA vaccines for COVID-19. There are numerous nanoparticle types, with properties including material composition, shape, size, surface functionalization, and antigen incorporation techniques affecting how vaccines are recognized, their cellular association, and antigen delivery. We are pleased to invite you to contribute to this Special Issue, which will showcase a collection of scientific papers on applications of nanoparticles in vaccines. Research areas may include (but are not limited to) nanoparticle-based vaccine development, antigen incorporation and vaccine design, modes of action, immune reactivity, applications and disease models and translation, including clinical trials. Original research articles and reviews are welcome.

Guest Editors

Dr. Kirsty Wilson

School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia

Prof. Dr. Magdalena Plebanski

School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia

Dr. Nhiem L. Tran

School of Science, RMIT University, Melbourne, Australia

Deadline for manuscript submissions

closed (28 February 2026)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/232150

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).